PubMed Health⌕ Search

Biomedical subjects

E Cope

Publications and source records attributed to E Cope.

At least 19 recordsLinked to original sources
PubMed1980

Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lack of effect of placebo.

In women with menorrhagia of unknown cause, the efficacy of the drug danazol in reducing heavy menstrual blood loss was investigated making objective measurements of menstrual blood loss. Drug regimens tested were daily administration of 200 or 100 mg danazol for 12 weeks and daily danazol given in the luteal phase or during menstruation. The results suggest that 200 mg danazol daily is the most acceptable regimen clinically since it significantly reduced menstrual blood loss and was associated with a relatively low incidence of side effects. In 16 women on this dose menstrual blood loss was suppressed from a mean pre-treatment loss of 183 +/- 25 ml to 38 +/- 11 ml (p < 0.01) in the second, and 26 +/- 9 ml (p < 0.01) in the third treatment months. The majority of women had regular episodes of bleeding with no alteration in cycle length and a reduction in the number of days of bleeding. Although 100 mg daily suppressed menstrual blood loss, particularly by the third month of treatment, it increased the number of episodes of bleeding in some women which they found unacceptable. Both 200 mg and 100 mg relieved dysmenorrhoea in the majority of women presenting with the symptoms. Danazol taken daily in the early follicular or luteal phase of the menstrual cycle did not significantly alter menstrual blood loss. There was no effect of placebo therapy on measured menstrual blood loss in a single blind trial in eight women with menorrhagia.

Adult↗
PubMed1980

Effect of danazol on serum gonadotrophins and steroid hormone concentrations in women with menorrhagia.

In 13 ovulatory women with objective evidence of menorrhagia (menstrual blood loss greater than 80 ml), danazol 400 mg given daily for 12 weeks suppressed ovulation as shown by absence of gonadotrophin peaks, low serum progesterone levels and flat basal body temperature recordings. Serum concentrations of luteinising hormone and follicle stimulating hormone were within the range found during the normal menstrual cycle but oestradiol concentrations tended to fall, reaching levels less than 100 pmol/l in some patients. Danazol treatment had no effect on levels of androstenedione or dehydroepiandrosterone and its sulphate. The presence or absence of cyclical bleeding on treatment, and the measured blood loss was unrelated to circulating oestradiol levels.

Adult↗
PubMed1979

The effect of danazol on menorrhagia, coagulation mechanisms, haematological indices and body weight.

Eighteen patients with objective evidence of menorrhagia (more than 80 ml menstrual blood loss) were treated with danazol for twelve weeks. Danazol significantly reduced the menstrual blood loss from 231 +/- 39 ml (mean +/- SEM) to 135 +/- 33 ml in the first treatment month and the mean loss thereafter was only 21 ml and 3 ml for the second and third months respectively. A rapid increase in haemoglobin level and a reduction in the number of days of bleeding were also observed on danazol treatment. No important effect on the coagulation profile was observed during the period of study. Three months after stopping danazol, menstrual blood loss (103 +/- 27 ml) was still significantly less than the pre-treatment loss.

Adult↗
PubMed1979

Preliminary results on clinical and endocrine studies in the treatment of menorrhagia with danazol.

Preliminary results are presented on the effect of 400, 200 and 100 mg of daily danazol on measured menstrual blood loss, in women with menorrhagia. Both 400 and 200 mg daily effectively suppressed menstrual blood loss, 400 mg reducing menstrual blood loss from a pretreatment mean of 456 +/- 48 ml to 45 +/- 26 ml and 6 +/- 5 ml during the second and third months of treatment. Menstrual blood loss on 100 mg danazol was only minimally reduced. After two to three months on danazol, the pituitary showed ability to respond to gonadotrophin releasing hormone and to oestradiol benzoate. A lack of effect of danazol on most coagulation and fibrinolytic factors was demonstrated.

Blood Coagulation Tests↗
PubMed1970

Treatment of menorrhagia with tranexamic acid. A double-blind trial.

In a double-blind trial tranexamic acid (Cyclokapron) 1 g. four times a day for the first four days of menstruation, significantly decreased menstrual blood loss in women with menorrhagia for which no organic cause had been found. No difference in side-effects was noted between the active and placebo treatment.

Adult↗
PubMed1969

Asymptomatic urinary tract infection in gynaecological outpatients.

In this study mid-stream specimens of urine were collected from all new patients attending a gynaecological outpatient department and tested for significant bacteriuria. Those having an asymptomatic infection were folloWed up, treated, and investigated adiologically.Of 1,506 women screened for bacteriuria 82 (5.4%) were found to have a persistent infection. The predominant organism was Escherichia coli, present in 83% of infections. Treatment with sulphonamides produced a good cure rate, which was improved by ampicillin given to failures. Some patients, however, had infections that persisted or recurred despite several antibiotics. The radiological investigations showed that a high proportion of women with asymptomatic urinary infection had severe renal disease which was quite symptomless. This was more pronounced in those with persistent or recurrent infections.

Ampicillin↗
PubMed1968

Gal'actorrhoea.

Explore the source record for details and available documents.

Adult↗